with R-salbutamol already being cleared and S-salbutamol reaching peak levels at Background -Racemic salbutamol re-30 minutes after the last dose (at t 110 ). mains one of the most commonly used There were higher plasma levels of R-salbronchodilators in the treatment of rebutamol and S-salbutamol following adversible airways obstruction. Data from ministration of the respective isomers animal and human studies suggest that the alone compared with their levels after ad-S-isomer, whilst contributing no bronchoministration of the racemate, suggesting dilator activity, may induce increased an influence of each isomer on the clearbronchial hyperreactivity and may explain ance of the opposite isomer when given as the adverse effects of regular racemic sala racemate. butamol on asthmatic disease control. The
The effects of the S isomer were in-2 agonists. 2 There is some evidence to suggest is known that tolerance develops to the prot 100 response as change from placebo); tection of salbutamol against direct and indirect studied in a double blind, crossover study to 1600 g/3200 g/6400 g). All treatments were
There were no significant differences between the four treatments for any of the measured given via a System 22 Sidestream nebuliser parameters.
(Medicaid, Pagham, UK) with a fill volume of 4 ml driven by compressed air at a flow rate of haled salbutamol there is an increase in both 8 l/min and nebulised to dryness. Doses were early and late airway responsiveness to given at 20 minute intervals (t 0 /t 20 /t 40 /t 60 /t 80 ). allergen.
5 8 Indeed, concomitant administration Measurements of extrapulmonary 2 responses of inhaled corticosteroid does not appear to were made over a five minute period at baseline prevent the increased airway responsiveness to and at 15 minutes after each dose administraallergen induced by regular salbutamol. 9 tion corresponding to t 0 /t 20 /t 40 /t 60 /t 80 /t 100 for each The mechanism behind these changes in dose level. Samples were also taken for airway responsiveness has been the topic of measurement of plasma salbutamol levels at 15 much research. The agonist activity of racemic minutes after each dose administration, with salbutamol is thought to reside solely with an extra sample taken at 30 minutes after the the R configuration. However, in sensitised last dose (t 110 ). All measurements were made guinea pigs the racemates and S isomers of with the subject supine. The subjects were isoprenaline, terbutaline, and salbutamol studied on four days, each separated by one have been shown to induce airway hyper-week. responsiveness.
10-12 The effects of racemic salbutamol and its constituent isomers, Rsalbutamol and S-salbutamol, have been evalu- ated in asthmatic subjects. 13 This revealed that Postural finger tremor was measured as prethe S isomer of salbutamol produced hyper-viously described with an accelerometer transresponsiveness to methacholine, whilst the R ducer (Entran, Ealing, UK).
14 Heart rate was isomer reduced hyperresponsiveness more measured from standard lead II of an electroeffectively when given alone than when ad-cardiogram monitor. Plasma potassium levels ministered as the racemate. However, these were assayed by flame photometry using an findings have been criticised in that the analysis IL943 analyser (Instrumentation Laboratory was performed on non-transformed skewed Ltd, Warrington, UK). The intra-assay and data, as well as reporting the final dose of interassay values for analytical imprecision were methacholine rather than the shift in PC 20 0.41% and 1.04%, respectively. The assay for value. We have evaluated for the first time the determination of plasma levels of R-and Spharmacokinetics and dose-response effects of salbutamol was made by high performance racemic (+/−) and the R (−) and S (+) liquid chromatography with fluorescence deisomers of inhaled salbutamol at extra-tection and was fully validated according to pulmonary 2 adrenoceptors in man. published guidelines 15 with a limit of quantitation of 0.25 ng/ml.
Methods

  
Twelve normal subjects of mean (SE) age 20.6  
The results were analysed using the "Stat-(0.40) years and forced expiratory volume in one second (FEV 1 ) of 108.9 (2.1)% were graphics" statistical software package (STSC Table 2 Values for extrapulmonary 2 Results are given as mean change from placebo with 95% CI for mean for t 100 and AUC only. Units for AUC: tremor (log units.h), potassium (mmol.h/l), heart rate (beats). * p<0.05 versus placebo for t 100 and AUC.
responses for R-salbutamol (R), S-salbutamol (S) and racemic salbutamol (RS) at each time point (20-100 minutes) and also for area under curve (AUC)
group.bmj.com on April 29, 2017 -Published by http://thorax.bmj.com/ Downloaded from data were calculated as area under the curve (AUC) in order to obviate multiple comparisons at each time point. For all parameters comparisons were made by multifactorial analysis of variance (MANOVA) and Duncan's multiple range testing was used to establish where the differences were significant for t 100 and AUC data only. A probability value of p < 0.05 (two tailed) was considered significant. The study was designed with 80% power (beta error=0.2) in order to detect a 20% difference in tremor between treatments. fig 1) . A plateau in the response was not reached within the administered dose range for R-salbutamol (3200 g) or RS-salbutamol (6400 g). No differences were found between R-and RSsalbutamol when compared on a 1:2 microgram basis. There were no differences between Ssalbutamol and placebo. For all 2 responses there were significant differences between Rand S-salbutamol isomers. beginning to fall, whilst levels of S-salbutamol reached their peak. Plasma levels of R-and Software Publishing Group, Rockville, USA). S-salbutamol were higher following adAll data were analysed as change from placebo ministration of the respective isomers alone with tremor data being log transformed as they than after administration of the racemate. were not normally distributed. Dose-response
Results

2  There were no differences in baseline values (t 0 ) between the four treatments (table 1). A dose-response effect was observed for R-salbutamol and RS-salbutamol but not for Ssalbutamol (table 2,
Discussion
The results of the present study show that Ssalbutamol has no activity at extrapulmonary 2 adrenoceptors whilst R-salbutamol and RSsalbutamol exhibit equivalent effects on a 1:2 microgram basis. It was noteworthy that plasma levels of S-salbutamol were consistently higher than R-salbutamol owing to greater clearance of the R isomer than the S isomer as was evident at 30 minutes after the last dose. Furthermore, higher plasma levels of R-and S-salbutamol occurred after administration of each isomer compared with levels after administration of the racemate, suggesting a possible influence of each isomer on the clearance of the opposite isomer when given as the racemate. The higher levels of R-salbutamol after administration of the R isomer alone compared with levels of R-salbutamol after administration of racemic salbutamol might partly explain previous ob- servations of greater bronchoprotection with
Figure 2 Mean plasma levels of R-salbutamol (R) and S-salbutamol (S) at 15 minutes
R-salbutamol than RS-salbutamol, although it after administration of cumulative doubling doses of R-, S-, and RS-salbutamol and at
would not explain the adverse effect of S- 
